AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in the development of antibody product candidates. The firm’s product pipeline includes ANB030, ANB030, and Imsidolimab. It also offers the SHM platform that replicates the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
52 week high is the highest price of a stock in the past 52 weeks, or one year. AnaptysBio Inc - When Issued - April 2026 52 week high is $49.76 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. AnaptysBio Inc - When Issued - April 2026 52 week low is $41.99 as of November 22, 2026.
AnaptysBio Inc - When Issued - April 2026 stock price today is $43.80.
AnaptysBio Inc - When Issued - April 2026 stock price yesterday was $43.00.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. AnaptysBio Inc - When Issued - April 2026 50-day moving average is $43.80.